Trumenba Injection, Suspension
Product Images NDC 0005-0100
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Trumenba (NDC 0005-0100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Wyeth Pharmaceutical Division Of Wyeth Holdings Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel (0.5 mL Syringe Label)
This is a description for a Meningococcal Group B Vaccine called "Trumenba" produced by Pfizer Inc. The provided information includes dosage information, NDC number, expiration date, and instructions to shake the vaccine vigorously before use. The vaccine is intended for intramuscular use only, requires refrigeration, and should not be frozen.*
Principal Display Panel (5)
This is the package insert for the Trumenba Meningococcal Group B Vaccine. It is a one-dose vaccine consisting of 0.5ml of solution in a pre-filled syringe, formulated to contain 60 micrograms of two factor H binding protein variants, 4380 micrograms Sodium Chloride, 18 micrograms Polysorbate 80, 780 micrograms Histidine, and 250 micrograms aluminum as aluminum phosphate. This vaccine is for individuals aged 10 through 25 years old and is for intramuscular use only. The prefilled syringe should be stored refrigerated and not be frozen. The package insert includes additional dosage and administration information. The vaccine is manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc, in Ireland.*
Principal Display Panel (10)
Trumenba is a meningococcal group B vaccine available in prefilled syringes for intramuscular use. Each 0.5 mL dose contains approximately 60 micrograms of two factor H binding protein variants, 4380 micrograms of sodium chloride, 18 micrograms of polysorbate 80, 780 micrograms of histidine, and 250 micrograms of aluminum 25 aluminum phosphate. The vaccine is indicated for individuals between the ages of 10 and 25. The prefilled syringe components do not contain natural rubber latex. Storage should be done in a refrigerated environment between 2°C to 8°C (36° to 46°F), and the vaccine should not be frozen. The packaging insert should be reviewed for additional dosage and administration information. The vaccine is manufactured by Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc.*
Principal Display Panel (1)
This is a description of a Meningococcal Group B vaccine called Trumenba. It is packaged in a one-dose prefilled syringe of 0.5 mL for intramuscular use only. The package includes information on dosage and administration. The vaccine contains 60 micrograms of each of two factor H-binding protein variants, one from subfamily A and one from subfamily B. It also includes other ingredients such as sodium chloride, polysorbate 80, histidine, and aluminum phosphate. The syringe tip and rubber plunger are not made with natural rubber latex. The package insert provides additional information. The vaccine must be stored refrigerated and should not be frozen. The manufacturer is Wyeth Pharmaceuticals, a subsidiary of Pfizer. The package is labeled with NDC 0005-0100-02 and GTIN: 0030050100027. LOT/EXP/SN information is not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.